ALINS Intrasense

Signature of 5-year agreement with LungAnalysis

Regulatory News:

Intrasense (FR0011179886 – ALINS) (Paris:ALINS), a global leader in multimodal medical imaging and oncology software, announces an agreement with LungAnalysis, Erasmus Medical Center’s core lab specialized in image analysis of lung diseases such as cystic fibrosis (CF), bronchiectasis, severe asthma and others. Erasmus MC is the largest Dutch university hospital and one of the top ten best medical institutes in Europe according to the Times Higher Education.

CF is a life shortening congenital disorder characterized by the progressive development of bronchiectasis. According to the latest WHO estimates (2004), currently 64 million people have COPD and 3 million people died of COPD. WHO predicts that COPD will become the third leading cause of death worldwide by 20301. In 2011, 12.7 million American adults (aged 18 and over) were estimated to have COPD, these being the third leading cause of death in America2.

Until recently, functional tests played the most important role for diagnosis and monitoring of most lung diseases. Over the last two decades, medical imaging (i.e. CT scanner) has been increasingly used for the diagnosis and follow-up of these lung diseases, for treatment planning and for the assessment of treatment response.

Erasmus MC has been an Intrasense scientific partner in the field of lung pathologies for several years. With this agreement, it extends the use of Myrian® to new advanced research activities, including academic clinical research, industry-sponsored trials and even patient care.

“Myrian® perfectly matches our needs”, adds Pr. Tiddens, Professor of Pediatric Respiratory Medicine at Erasmus University Medical Center and Sophia Children's Hospital. “It is a reliable, flexible and easy-to-use solution. The advanced and unique capabilities of its clinical application Myrian® XP-Lung allows us to measure specific imaging biomarkers. This is key for the optimal evaluation of response to treatment in an accurate, reproducible and timely manner. Over the years of our collaboration Intrasense has been a very loyal partner adapting Myrian® to the needs of our research.”

This collaboration validates Intrasense strategy and ability to take advanced technology from clinical research to routine radiology: “We are very happy about this agreement with one of the most prestigious hospitals worldwide. It highlights Myrian® pioneering ability to fulfill image-based needs in clinical care and in clinical research”, comments Stéphane Chemouny, Intrasense Scientific Director and Chairman.

1 http://www.who.int/respiratory/copd/en/2 http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html

About Erasmus MC:Erasmus MC is the largest and most authoritative scientific University Medical Center in the Netherlands. Almost 13,000 staff members work within the core tasks of patient care, education, and scientific research on the continuous improvement and enforcement of individual patient care and social healthcare. They develop high-level knowledge, pass this on to future professionals, and apply it in everyday patient care. Over the next five years, Erasmus MC wants to grow into one of the best medical institutes in the world. Erasmus MC is part of the Dutch Federation of University Medical Centers (NFU).

For information about Erasmus MC, please visit www.erasmusmc.nl.

About Intrasense:Created in 2004 with an innovative technology of tissues detection in CT scan, Intrasense designs, develops and markets Myrian®, a unique, vendor-neutral software suite for the visualization and advanced processing of multimodal medical images such as MRI, CT scans, PET, X-rays, and more. Developed with leading academic and scientific partners, Myrian® combines and uses all of the various medical images to extract information vital to the patient's care, to evaluate treatment efficiency and to assess drug candidates in oncology and other pathologies. With more than 700 client sites around the world, Myrian® has been certified as a "medical device" in over 40 countries including the United States (FDA), Europe (CE) and Asia. Intrasense SA is listed on the Alternext (FR0011179886 - ALINS). The company employs 70 people, including 25 dedicated in R&D. Labelled “innovative company” by Oseo, Intrasense has invested over 9 M€ in R&D since its creation.For more about Intrasense, please visit www.intrasense.fr and follow us on LinkedIn.

IntrasensePatrick MayetteChief Executive OfficerChristophe LamboeufChief Financial OfficerPhone: (33) (0)1 48 04 32 83investor@intrasense.frorNewCapFinancial disclosure and investor relationsValentine Brouchot / Pierre LaurentPhone: (33) (0)1 44 71 94 96intrasense@newcap.fr

Intrasense (EU:ALINS)
Historical Stock Chart
From Oct 2024 to Nov 2024

Intrasense (EU:ALINS)
Historical Stock Chart
From Nov 2023 to Nov 2024